Approaches Toward Improving the Prognosis of Pediatric Patients With Glioma: Pursuing Mutant Drug Targets With Emerging Small Molecules

Abstract

Gliomas represent approximately 70% of all pediatric brain tumors and most of these are of astrocytic lineage, furthermore, malignant or high-grade astrocytoma account for approximately 20% of pediatric astrocytoma. Treatment options for pediatric glioma patients are limited. Although low-grade astrocytoma are relatively slow-growing tumors which can often be cured through surgical resection, a significant proportion of cases will recur, as such new treatments are desperately needed. This review covers the various approaches that are currently being made towards improving the prognosis of pediatric glioma patients by pursuing pediatric-selective mutant drug targets with emerging small molecules.